Elevance Health Inc. (NYSE: ELV) is a Healthcare company (Medical - Healthcare Plans) with a market capitalization of $94.5B. The Maz Rating grades it against the other companies in its sector.
Elevance Health Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $437.50, Elevance Health Inc. trades at 19.0x trailing earnings, 0.5x sales and 2.2x book value, with an EV/EBITDA of 13.2. Over the last twelve months it generated about $197.9B of revenue and $5.0B of net income. It runs a gross margin of 36.6%, an operating margin of 3.7% and a net margin of 2.5%. It shows return on equity of 11.6%, return on invested capital of 7.5% and a free cash flow yield of 6.8%. On the balance sheet: a debt-to-equity ratio of 0.69 and a current ratio of 1.47. Over the past 52 weeks the share price ranged from $274.84 to $450.69, with a beta of 0.71.
Elevance Health Inc. pays a dividend yielding 1.54%, with 29% of earnings paid out. Its Maz Dividend Score is 4.03 out of 5, ranked against the other dividend payers in its sector (Safety 3.10, Growth 3.37, Yield 3.63, Consistency 3.47).
38 Wall Street analyst ratings cover the stock: 27 Buy and 11 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Operating as a major health benefits organization, Elevance Health Inc. commits to guiding consumers, families, and communities across their entire health and wellness path. It facilitates access to vital care, assistance, and tools designed to enable healthier living for approximately 118 million individuals. The company's comprehensive offerings span medical, digital, pharmaceutical, behavioral health, clinical, and other care solutions. Founded in 1944 and based in Indianapolis, Indiana, this entity adopted its current name, Elevance Health Inc., in June 2022, having previously operated as Anthem, Inc.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Elevance Health Inc. (ELV) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 34.2% / 30% · (Cash+Inv) / Mkt Cap (36m) 56.2% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 34.2% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 42.1% / 33% · Receivables / Mkt Cap (36m) 27.3% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 34.2% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 42.1% / 33.33% · Receivables / Mkt Cap (24m) 27.3% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 25.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 24.0% / 33.33% · Receivables / Avg Assets (4Q) 17.1% / 33.33% · Interest income / Revenue 0.00% / 5% | Pass |
| FTSE | Debt / Total Assets 24.1% / 33.33% · (Cash+ST Inv) / Total Assets 29.6% / 33.33% · (Cash+Recv) / Total Assets 48.8% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Elevance Health Inc. (ELV) passes 1 of 5 published Shariah screening standards checked by Maz Vantage: it passes MSCI, and fails AAOIFI, S&P Global, Dow Jones and FTSE.
No. Elevance Health Inc. is over the AAOIFI limit on Debt / Mkt Cap (36m) and (Cash+Inv) / Mkt Cap (36m).
Elevance Health Inc. reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.